More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.

The company makes no secret of the need for durability with its anti-CD47 project SL-172154.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.